The Egyptian Journal of Hospital Medicine (October 2017) Vol.69 (3), Page 2075-2081

Rubella and Congenital Rubella Syndrome in Pediatric

Ashwaq Ali Absalem[1], Rola Mohammed Alanazi[2], Sajida Hassan Alkhawajah[3], Ohoud Ahmed Hijazi[4], Fahad Abdulaziz Jarad[5], Bassmah Hassan Alrowaithi[6], Zahra Jaber Hussein[7], Faris Hussain Al-Ameer[7], Afnan Ahmed Aljehani[6], Amina Bashir Shikeh Adam[8]

1 Tabuk University,2 King Fahad Armed Forces Hospital –Jeddah,
3 Maternity and Child Hospital (MCH) Dammam,4 Taif University, 5 King Khalid University,
6 Ibn Sina National College for Medical Studies,7 Imam Abdulrahman Bin Faisal University,
Dammam, Saudi Arabia,8 Banadir University
Corresponding Author: Ashwaq Ali Absalem - as.aL93@hotmail.com

ABSTRACT

The name rubella is derived from a Latin expression signifying "minimal red". Rubella is, for the most part, a benign transferable exanthematous disease. It is caused by rubella virus, which is an affiliate of the Rubivirus class of the family Togaviridae. About half of people contaminated with rubella are asymptomatic. Clinical indications and severity of disease fluctuate with age. For example, contamination in children is portrayed by mild constitutional symptoms, suboccipital adenopathy, and rash; on the other hand, in adolescents and adults, rubella might be complicated by arthritis, thrombocytopenic purpura, and arthralgia. Uncommon cases of rubella encephalitis have likewise been depicted in children. The main complication of rubella is its teratogenic impacts when pregnant ladies get the disease, particularly in the early weeks of pregnancy. The virus could be transmitted to the fetus through the placenta and is equipped for causing genuine congenital defects, stillbirths, and abortions. Fortunately, as a consequence of the successful vaccination program, rubella contamination and congenital rubella syndrome infrequently are seen today. We conducted this review using a comprehensive search of MEDLINE, PubMed, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials from January 1, 1970, through February 28, 2017. The following search terms were used: rubella, rubella syndrome, congenital, paediatric rubella, vaccination, rubella-containing vaccine, and rubella immunization campaigns.

Keywords: rubella, rubella syndrome, congenital, children, vaccination.

INTRODUCTION

Rubella infection is generally mild with nonspecific symptoms and is hence regularly undiagnosed or misdiagnosed. Though, the rubella virus remains a significant public health problem because of the teratogenic effects and danger of miscarriage and stillbirth that can result from congenital infection, mostly when the mother becomes infected throughout the first period of pregnancy [1, 2, 3]. With the utilization of viable rubella vaccines, rubella was focused for elimination in two districts of the World Health Organization (WHO) by 2015. However by the end of 2015, just the Region of the Americas was proclaimed to be free of endemic rubella transmission. Around the world, utilization of rubella-containing vaccine (RCV) is expanding in spite of RCV presentation in 74% of 194 WHO part states, in 2014, worldwide new-borns vaccination scope stayed low at 46% [4]. Surveillance for rubella and CRS is pivotal in checking the effect of inoculation projects to survey infection trouble previously, then after the fact RCV presentation. In spite of the fact that rubella reconnaissance is being directed in many nations in conjunction with measles observation,

observation exercises for CRS, especially in creating nations, have ended up being all the more difficult. Out of 194 part states, just 75 nations started detailing in 2000, which expanded to 114 of every 2014 except just 14 nations revealed positive case recognizable proof [4, 5]. In this way, the genuine weight of CRS remains underestimated [6].

Since 2003, the Western Pacific Region of the World Health Organization (WHO) has determined to accelerate the control of rubella and avoidance of CRS through integration with measles elimination activities [7]. In 2014, the Western Pacific Region involved rubella including CRS elimination as one of eight regional immunization objectives quantified by the Regional Framework for Implementation of the Global Vaccine Action Plan in the Western Pacific [8]. Surveillance for rubella was incorporated into the measles surveillance in 2010; though passive laboratory-confirmed surveillance for rubella has been

Received: 22 / 7 /2017
Accepted: 1 /8 /2017
DOI : 10.12816/0041062

conducted since 2005. In 2009 and 2010, there were 310 and 1,092 serologically confirmed rubella cases out of 1,279 and 4,085 specimens tested, respectively, worldwide [9].

MATERIALS AND METHODS

- **Data Sources and Search terms**
  We conducted this review using a comprehensive search of MEDLINE, PubMed, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials from January 1, 1970, through February 28, 2017. The following search terms were used: rubella, rubella syndrome, congenital, paediatric rubella, vaccination, rubella-containing vaccine, and rubella immunization campaigns.

- **Data Extraction**
  Two reviewers independently reviewed studies, abstracted data, and resolved disagreements by consensus. Studies were evaluated for quality. A review protocol was followed throughout.

Causes of Rubella and Congenital Rubella Syndrome

Rubella and congenital rubella syndrome are caused by rubella virus. Only one antigenic form of rubella virus is available, and humans are the only natural hosts. The virus is spherical with a diameter of 50-70 nm, has a central core (ie, nucleocapsid), and is covered on the outside by a lipid-containing envelope. The nucleocapsid is composed of polypeptide (C protein) and a single-stranded RNA. Its outer envelope is made up of glycosylated lipoprotein, which includes 2 virus-specific polypeptides (E1, E2) and a host-cell–derived lipid. These 2 envelope proteins include the spiked 5-nm to 6-nm surface projections that are observed on the outer membrane of rubella virus and are significant for the virulence of the virus. Monoclonal antibodies directed against epitopes of E1 and E2 have neutralizing activity. Protein E1 is the viral hemagglutinin that binds both hemagglutination-inhibiting and hemolysis-inhibiting antibodies. Rubella virus is quickly inactivated by 70% alcohol, ethylene oxide, deoxycholate, ultraviolet light, acetone, formalin, chloroform, free chlorine, beta-propiolactone, ether, extreme pH (< 6.8 or > 8.1), heat greater than 56°C, and cold from -10°C to -20°C. It is resistant to thimerosal and is steady at a temperatures of -60°C or less [10, 11].

Congenital Rubella Syndrome

The classic triad presentation of congenital rubella syndrome consists of the following:

Sensorineural hearing loss is the most well-known demonstration of congenital rubella syndrome. It happens in around 58% of patients. Studies have exhibited that around 40% of patients with congenital rubella syndrome might present with deafness as the main anomaly without other manifestations. Hearing loss might be bilateral or unilateral and might not be clear until the second year of life.

Ocular abnormalities containing cataract, pigmentary retinopathy, and infantile glaucoma happen in roughly 43% of children with congenital rubella syndrome. The two eyes are influenced in 80% of patients, and the most regular findings are cataract and rubella retinopathy. Rubella retinopathy contains of a salt-and-pepper pigmentary change or a mottled, irregular pigmentation, blotchy, frequently with the greatest density in the macula. The retinopathy is amiable and nonprogressive and does not interfere with vision (in compare to the cataract) except choroid neovascularization improves in the macula [12].

Congenital heart ailment containing patent ductus arteriosus (PDA) and pulmonary artery stenosis is current in 50% of children infected in the first 2 months' gestation. Cardiac deficiencies and deafness happen in all new-borns infected during the first 10 weeks of pregnancy and deafness only is noted in one third of those contaminated at 13-16 weeks of gestation [13].

Table 1: Clinic pathologic Defects in Congenital Rubella

Abnormality	Common/Uncommon	Early/Delayed	Comment
General			
Intrauterine growth retardation	Common	Early	...
Prematurity	Uncommon	Early	...
Stillbirth	Uncommon	Early	...
Abortion	Uncommon	Early	...
Cardiovascular system			
Patent ductus arteriosus	Common	Early	May occur with pulmonary artery stenosis
Pulmonary artery stenosis	Common	Early	Caused by intimal proliferation
Coarctation of the aorta	Uncommon	Early	...
Myocarditis	Uncommon	Early	...
Ventricular septal defect	Uncommon	Early	...
Atrial septal defect	Uncommon	Early	...
Ear			
Hearing loss	Common	Early/Delayed	Usually bilateral; mostly sensorineural; may be central in origin; rare when maternal rubella occurs >4 months' gestation; sometimes progressive
Eye			
Cataract	Common	Early	Unilateral or bilateral
Retinopathy	Common	Early	Salt-and-pepper appearance; visual acuity unaffected; frequently unilateral
Cloudy cornea	Uncommon	Early	Spontaneous resolution
Glaucoma	Uncommon	Early/Delayed	May be bilateral
Microphthalmia	Common	Early	Common in patients with unilateral cataract
ubretinal neovascularization	Uncommon	Delayed	Retinopathy with macular scarring and loss of vision
Skin			
Blueberry muffin spots	Uncommon	Early	Represents dermal erythropoiesis
Chronic rubelliform rash	Uncommon	Early	Usually generalized; lasts several weeks
Dermatoglyphic abnormalities	Common	Early	...
Lungs			
Interstitial pneumonia	Uncommon	Delayed	Generalized; probably immunologically mediated
Liver			
Hepatosplenomegaly	Common	Early	Transient
Jaundice	Uncommon	Early	Usually appears in the first day of life
Hepatitis	Uncommon	Early	May not be associated with jaundice
Bone			
Radiographic lucencies	Common	Early	Transient; most common in distal femur and proximal tibia

Large anterior fontanel	Uncommon	Early	...
Micrognathia	Uncommon	Early	...
Immune system			
Hypogammaglobulinemia	Uncommon	Delayed	Transient
Lymphadenopathy	Uncommon	Early	Transient
Thymic hypoplasia	Uncommon	Early	Fatal
Blood			
Thrombocytopenia	Common	Early	Transient; no response to steroid therapy
Anemia	Uncommon	Early	Transient
Hemolytic anemia	Uncommon	Early	Transient
Altered blood group expression	Uncommon	Early	...
CNS			
Meningoencephalitis	Uncommon	Early	Transient
Microcephaly	Uncommon	Early	May be associated with normal intelligence
Intracranial calcifications	Uncommon	Early	...
Encephalographic abnormalities	Common	Early	Usually disappear by age 1 y
Mental retardation	Common	Delayed	...
Behavioral disorders	Common	Delayed	Frequently related to deafness
Autism	Uncommon	Delayed	...
Chronic progressive panencephalitis	Uncommon	Delayed	Manifest in second decade of life
Hypotonia	Uncommon	Early	Transitory defect
Speech defects	Common	Delayed	Uncommon in absence of hearing loss
Endocrine glands			
Diabetes mellitus	Common	Delayed	Usually becomes apparent in second or third decade of life
Thyroid disease	Uncommon	Delayed	Hypothyroidism, hyperthyroidism, and thyroiditis
Growth hormone deficiency	Uncommon	Delayed	...
Genitourinary system			
Cryptorchidism	Uncommon	Early	...
Polycystic kidney	Uncommon	Early	...

Rubella elimination Approaches:

Approaches for rubella elimination can be divided into those four:

- Countries that introduced an rubella-containing vaccine more than 20 years ago in a routine childhood vaccination programs
- Countries that have conducted a mass rubella immunization campaigns (aiming both males and females)
- Countries that have conducted partial rubella immunization activities (by cohort, sex, risk group, or geographic area)
- Countries that have not yet introduced a rubella-containing vaccine in their childhood vaccination programs.

Other vaccination approaches (e.g., institutional immunization programs, immunization of concentrated populations, and door-to-door vaccination programs) may similarly be used liable on the target population, the features of the department or district with different geographic and socioeconomic regions, implementation the rubella elimination campaign, and the phase of the campaign. Vaccination of concentrated populations ought to be based on census lists by target age group. Institutional vaccination programs must focus on women of pregnancy age such as hospital vaccination of women post-delivery. Door-to-door vaccinations can be utilized to cover exposed populations not reached by health services or fixed

vaccination posts. For school-aged children, containing vaccination as a school-entry requirement has proved to be an active approach for succeeding and maintaining high vaccine exposure [14]. The establishment of local committees for technical, political, and operational support appears to be vital for enhancing the coordination and execution of rubella elimination approaches, and the establishment of a broad partnership through outreach to numerous areas of society (e.g., public safety, education, and religious gatherings; nongovernmental organizations (NGOs); community leaders; industry and trade groups; and professional associations and scientific societies) is vital. Similarly, working with government and international agencies, containing WHO, offers help all through crusade arranging and implementation. At last, having encountered vaccination campaign administrators, utilizing graphs and activity timetables to control progress, and having fast access to all accessible data might be useful at the operational level, and innovative promotion techniques, containing local participatory events, highly visible messages, and advertising, can help expand community awareness of the significance of avoiding rubella and CRS [15, 16].

Vaccination programs Strategies

Including the rubella vaccine into routine childhood vaccination plans is a cost beneficial and cost effective method of avoiding congenital rubella infection and CRS [17]. Nations must just consider this methodology if they are capable to achieve and maintain 80% or higher coverage with their consistent childhood measles vaccination campaigns [18]. Containing an RCV in consistent childhood measles vaccination promotions that cover less than 80% of the child population can result in declined rubella virus circulation, which could expand the normal period of rubella disease for females from youth to the childbearing years. As a result, in situations where regular childhood measles vaccination coverage is less than 80%, to protect women of childbearing age from giving birth to babies with CRS, mass immunization of each person less than forty years old with the measles-rubella (MR) vaccine is suggested [19]. A recent study of rubella vaccination methodologies executed in the Americas found that a mix of the two sorts of mass vaccination programs (routine child immunization and mass inoculation of all guys and females matured 5-39+ years) prompted the interference of rubella infection dissemination, the end of endemic ailment, and the anticipation of CRS, in a shorter timeframe than anticipated, contrasted and routine adolescence inoculation alone or in mix with hazard lessening approaches for the grown-up populace, for example, baby blues inoculation and screening programs for insusceptibility [20]. In any case, other research demonstrated that resistance screening joined with particular baby blues inoculation can altogether lessen both the quantity of helpless ladies and the number who encounter rubella contamination amid pregnancy [21, 22].

Vaccine schedules, dosage, and formulations

Rubella vaccines are accessible in monovalent formulations and in mixture with other vaccine viruses (RCV). One dose of either sort of vaccine is suggested for Childs less than 12 months old to avoid rubella. Follow-up studies specify that one dose of rubella vaccine could offer long-lasting immunity and that an RCV delivers safety from the infection (low vulnerability to rubella disease), with antibody levels reducing over time [23]. Notwithstanding these results, most countries presently have a two dose vaccine schedule (with the first dose managed at age 12-15 months and the second at age 3-5 years) utilizing an RCV-the joined measles-mumps-rubella (MMR) vaccine. This is a practical technique, since the clinical symptoms of rubella and measles are comparable and rubella and measles influence the similar age groups [24].

Treatment of rubella and CRS

Treatment of rubella is helpful. No exact antiviral agent for rubella is presently available. Starch baths and antihistamines can be beneficial for adult patients with uncomplicated rubella and troublesome itching.

For complicated cases, treatment is as follows:

- For patients with encephalitis, offer supportive care with suitable fluid and electrolyte maintenance.
- Thrombocytopenia is typically self-limited nonetheless, if severe, think through intravenous immunoglobulin (IVIG). Corticosteroids have not validated any specific advantage. Splenectomy is not specified.
- For severe arthritis affecting weight-bearing joints, inspire rest. Nonsteroidal anti-inflammatory drugs (NSAIDs) might be useful, but corticosteroids are not specified.

Congenital rubella syndrome treatment is supportive. Offer vision screening and hearing screening for asymptomatic new-borns.

Treatment of symptomatic new-borns is as follows:

- Children with congenital rubella syndrome who improve respiratory distress might need supportive management in the ICU.

- Provide careful assessment of the eyes and ophthalmology referral for children with corneal clouding, cataract, and retinopathy. Corneal clouding might show infantile glaucoma.
- Infants who have a rubella-related heart abnormality should be carefully observed for signs of congestive heart failure. Echocardiography may be essential for diagnosis of heart defects.
- Patients with hyperbilirubinemia might need phototherapy or exchange transfusions if jaundice is severe to avoid kernicterus.
- True hemorrhagic problems have not been a main problem; nevertheless, IVIG might be considered in infants who develop severe thrombocytopenia. Corticosteroids are not specified.
- Hepatosplenomegaly is observed clinically. No intervention is needed.

Contact isolation is essential for patients with congenital rubella throughout hospitalizations as babies are infected at birth and are normally contagious until older than 1 year except if viral cultures have produced negative outcomes [25, 26].

CONCLUSIONS

One single mass national immunization promotion focusing on all men and women 5-39+ years of age and combination of an rubella-containing vaccine in routine childhood vaccination programs, including regular vaccination promotions for 12-month-olds, can eliminate rubella and congenital rubella syndrome.

Nevertheless, importations of rubella viruses from different nations and areas through travel and migration are genuinely normal and may lead to outbursts and even re-establish widespread transmission of the disease. Thus, notwithstanding mass vaccination, the following measures ought to be taken to assist prevent rubella and congenital rubella syndrome: surveillance of the quantity of disposed women of childbearing age, and the development of imported cases; scope of powerless populaces with additional opportunity (catch-up) campaigns (vaccination of older children and adults who might have missed earlier vaccination programs); fast and fitting reaction to outbreaks; reinforcement of congenital rubella syndrome surveillance; participation of the private sector in awareness and vaccination promotions; and decrease the quantity of false-positive laboratory test results.

REFERENCES

1. **Hobman T and Chanter J(2007).** Rubella virus. In: Knipe DM, Howley PM. Fields virology. 5th ed. Philadelphia: Wolters Kluwer, Pp. 1069-100.
2. **Cooper LZ(2004).** The burden of congenital rubella syndrome. In: de Quadros CA, editor. Vaccines: preventing disease & protecting health. Washington: Pan American Health Organization,Pp. 53-64.
3. **Gillam S(1994).** The Jeanne Manery Fisher Memorial Lecture 1994. Molecular biology of rubella virus structural proteins. **Biochem Cell Biol.** ,72(9-10):349-56.
4. **Grant G, Reef S, Dabbagh A, Gacic-Dobo M and Strebel P(2015).** Global progress toward rubella and congenital rubella syndrome control and elimination-2000–2014. **The Weekly Epidemiological Record**. ,90(39):510–516.
5. **World Health Organization(2016).** WHO-vaccine preventable diseases monitoring system 2015 global summary Geneva. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidencecrs.html.
6. **Adam O, Ali A, Hübschen Jand Muller C (2014).** Identification of congenital rubella syndrome in Sudan. BMC Infectious Diseases,1-14
7. **World Health Organization(2012).** elimination of measles and rubella control. Regional Office of the Western Pacific. Regional Committee for the Western Pacific: WPR/RC63.R5. Manila, Pa, USA: www.wpro.who.int/.../measles_elimination_verification_guidelines_2013.pd
8. **WHO(2014).** Expanded Programme on Immunization: Regional framework for Implementation of the Global Vaccine Action Plan in the Western Pacific Manila: Regional Office of the Western Pacific. Geneva, Switzerland: WHO. http://www.wpro.who.int/about/regional_committee/65/documents/wpr_rc065_08_epi_en.pdf.
9. **World Health Organization(2010).** Measles-Rubella Bulletin. Manila, Philippines: Regional Office for the Western Pacific Region. http://iris.wpro.who.int/bitstream/handle/10665.1/11129/Measles-Rubella_Bulletin_2010_Vol_04_No_03.pdf?sequence=1.
10. **Forrest JM, Turnbull FM, Sholler GF *et al.* (2002).** Gregg's congenital rubella patients 60 years later. Med. J. Aust. ,177 (11–12): 664–7.
11. **Honeyman MC, Dorman DC, Menser MA, Forrest JM, Guinan JJ and Clark P (1975).** HL-A antigens in congenital rubella and the role of antigens 1 and 8 in the epidemiology of natural rubella. Tissue Antigens,5 (1): 12–8.
12. **CDC Centers for Disease Control and Prevention(2005).** Morbidity and Mortality Weekly Report. Achievements in Public Health: Elimination of Rubella and Congenital Rubella Syndrome—United States. JAMA. , 293:2084-6.
13. **Santos-Cabaero A, Malanyaon O, Ty E and Ortiz E (1998).** Profile of congenital heart disease in Filipino children with congenital rubella syndrome. Philippine Journal of Pediatrics,47(1):52–54.
14. **Watson JC, Hadler SC, Dykewicz CA, Reef S and Phillips L(1998).** Measles, mumps, and rubella-

vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.,47(RR-8):1-57.

15. **Urquijo L, Pastor D, Velandia MP and Vicari AS (2011).** Rubella and congenital rubella syndrome elimination activities: Colombia.J Infect Dis.,204 Suppl 2:S603-7.
16. **Andrus JK, de Quadros CA (2013).** Perspectives on the role of surveillance in eliminating rubella and congenital rubella syndrome in the Americas. Expert Rev Vaccines,12(9):989-93.
17. **Hinman AR, Irons B, Lewis M and Kandola K (2002).** Economic analyses of rubella and rubella vaccines: a global review. Bull World Health Organ.,80(4):264-70.
18. **Centers for Disease Control and Prevention (US)(2012).** Documentation and verification of measles, rubella and congenital rubella syndrome: elimination in the region of the Americas. United States national report. CDC Report: Elimination of Measles, Rubella, and CRS. Atlanta: CDC National Center for Immunization and Respiratory Disease; 2012. Available from: http://www.cdc.gov/measles/downloads/report-elimination-measles-rubella-crs.pdf
19. **Andrus JK, de Quadros CA, Solórzano CC, Periago MR and Henderson DA (2011).** Measles and rubella eradication in the Americas. Vaccine,29 (4):D91-6.
20. **Mongua-Rodriguez N, Díaz-Ortega JL, García-García L, Piña-Pozas M, Ferreira-Guerrero E, Delgado-Sánchez G *et al.*(2013).** A systematic review of rubella vaccination strategies implemented in the Americas: impact on the incidence and seroprevalence rates of rubella and congenital rubella syndrome. Vaccine,31(17):2145-51.
21. **Okuda M, Yamanaka M, Takahashi T, Ishikawa H, Endoh M and Hirahara F (2008).** Positive rates for rubella antibody in pregnant women and benefit of post-partum vaccination in a Japanese perinatal center. J Obstet Gynaecol Res.,34(2):168-73.
22. **Griffiths PD and Baboonian C(1982).** Is post-partum rubella vaccination worthwhile? J Clin Pathol. ,35(12):1340-4.
23. **McLean HQ, Fiebelkorn AP, Temte JL and Wallace GS (2013).** Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.,62(RR-04): 1-34.
24. **Watson JC, Hadler SC, Dykewicz CA, Reef S and Phillips L (1998).** Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.,47(RR-8):1-57.
25. **Pandolfi E, Chiaradia G, Moncada M, Rava L and Tozzi AE (2009).** Prevention of congenital rubella and congenital varicella in Europe. Euro Surveill.,14(9):16-20.
26. **Rafiei Tabatabaei S, Esteghamati AR, Shiva F, Fallah F, Radmanesh R, Abdinia B *et al.*(2013).** Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children. Arch Iran Med., 16(1):38-41.